PARP1 and neoplasm: Mice were treated with rucaparib for 20 consecutive days, and the following parameters were analyzed: (1) total body, muscle, tumor weights, and tumor area; (2) limb muscle strength, and physical activity; (3) muscle structural abnormalities and damage; (4) muscle phenotype; (5) PARP activity; and (6) markers of muscle proteolysis and autophagy.